IL197362A0 - Method for reducing or alleviating inflammation in the digestive tract - Google Patents

Method for reducing or alleviating inflammation in the digestive tract

Info

Publication number
IL197362A0
IL197362A0 IL197362A IL19736209A IL197362A0 IL 197362 A0 IL197362 A0 IL 197362A0 IL 197362 A IL197362 A IL 197362A IL 19736209 A IL19736209 A IL 19736209A IL 197362 A0 IL197362 A0 IL 197362A0
Authority
IL
Israel
Prior art keywords
reducing
digestive tract
alleviating inflammation
subject
alleviating
Prior art date
Application number
IL197362A
Other languages
English (en)
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Publication of IL197362A0 publication Critical patent/IL197362A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL197362A 2006-09-08 2009-03-03 Method for reducing or alleviating inflammation in the digestive tract IL197362A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US82780706P 2006-10-02 2006-10-02
PCT/US2007/077857 WO2008031014A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Publications (1)

Publication Number Publication Date
IL197362A0 true IL197362A0 (en) 2009-12-24

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197362A IL197362A0 (en) 2006-09-08 2009-03-03 Method for reducing or alleviating inflammation in the digestive tract

Country Status (11)

Country Link
US (1) US20080234345A1 (enExample)
EP (1) EP2059234B1 (enExample)
JP (1) JP2010502736A (enExample)
CN (1) CN101568331A (enExample)
AT (1) ATE531362T1 (enExample)
AU (1) AU2007292247A1 (enExample)
CA (1) CA2662535A1 (enExample)
DK (1) DK2059234T3 (enExample)
ES (1) ES2376493T3 (enExample)
IL (1) IL197362A0 (enExample)
WO (1) WO2008031014A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP2011513491A (ja) * 2008-03-10 2011-04-28 オレ・ファーマシューティカルズ・インコーポレーテッド 近位消化管の障害の治療
US20100204286A1 (en) * 2009-02-12 2010-08-12 Donahue Stephen R Method for reducing gastrointestinal adverse effects of cytotoxic agents
JP5845171B2 (ja) * 2010-03-04 2016-01-20 大日本住友製薬株式会社 炎症性腸疾患用薬剤
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
IL146000A0 (en) * 1999-04-30 2002-07-25 Millennium Pharm Inc Ace-2 inhibiting compounds and methods of use thereof
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CA2509526A1 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
WO2008031013A1 (en) * 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
ES2376493T3 (es) 2012-03-14
US20080234345A1 (en) 2008-09-25
WO2008031014A1 (en) 2008-03-13
DK2059234T3 (da) 2011-11-28
EP2059234B1 (en) 2011-11-02
AU2007292247A1 (en) 2008-03-13
EP2059234A1 (en) 2009-05-20
JP2010502736A (ja) 2010-01-28
AU2007292247A2 (en) 2009-03-26
CA2662535A1 (en) 2008-03-13
ATE531362T1 (de) 2011-11-15
CN101568331A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
IL197362A0 (en) Method for reducing or alleviating inflammation in the digestive tract
WO2009055783A3 (en) Anti-pcsk9 and methods for treating lipid and cholesterol disorders
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
MY158504A (en) Fatty acid niacin conjugates and their uses
IL197350A0 (en) Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
MX337634B (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos.
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
EP2671891A3 (en) Ang-2 inhibition to treat multiple sclerosis
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
WO2008139263A3 (en) Methods for slowing the progression of multiple sclerosis
WO2010062900A3 (en) A new family of pain producing substances and methods to produce novel analgesic drugs
WO2006132959A3 (en) Inhibition of thrombin generation
HRP20190377T1 (hr) Uporaba alfa-ketoglutarne kiseline i 5-hidroksi metilfurfurala za smanjenje oksidativnog stresa
CA2837895C (en) Methods of treating or preventing neurological diseases
NZ593019A (en) Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
WO2007147868A3 (en) Prevention of muscle atrophy
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
WO2007103727A3 (en) Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of nf-kb
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
WO2008042892A3 (en) Fatty acid amide hydrolase inhibitors for energy metabolism disorders
WO2011038924A3 (en) Proteasome inhibitors for treating cancer
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
WO2009114088A3 (en) Fullerene therapies for inflammation